Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onglyza

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

Merck & Co stops development of Januvia, atorvastatin combo

Company spokesperson claims decision is for “business reasons”

german flag

AZ sees Seroquel XR patent overturned in Germany

Follows challenge by Teva, Hexal and Accord Healthcare

- PMLiVE

AZ drug for opioid constipation clears phase III

Company hopes to file naloxegol in third quarter of 2013

- PMLiVE

Lilly launches diabetes partnership programme in South Africa

Partners with Project Hope and Donald Woods Foundation

- PMLiVE

Boehringer moves interferon-free hep C regimen into phase III

Oral combination drug achieved viral cure rate of up to 85 per cent in phase IIb

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

UK flag

MRC funds UK research using 22 AstraZeneca compounds

Provides £7m for projects covering Alzheimer’s, cancer, lung disease and rare conditions

- PMLiVE

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

- PMLiVE

New CEO says AZ open to acquisitions to rebuild pipeline

Comments come as Q3 operating profit plummets 47 per cent

- PMLiVE

AstraZeneca signs IBS collaboration with Ironwood in China

Deal will also see Ironwood’s US sales force promote Nexium for gastroesophageal reflux disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links